Jeito Capital

Jeito Capital is a global private equity fund specializing in life sciences, with a strong focus on biopharma companies. Founded in Paris, Jeito supports breakthrough innovations that address critical unmet medical needs. The fund's mission is centered on improving patient outcomes through targeted investments in early-stage and growth-stage biopharma companies, particularly those working on therapies for life-threatening diseases. Jeito operates with a unique long-term investment strategy, providing continuous financial support from clinical development through to market access. This allows its portfolio companies to achieve significant milestones while accelerating drug development. The fund has a diverse portfolio of companies, including SparingVision, which is developing gene therapy treatments for inherited retinal diseases, and CatalYm, a biopharma firm working on novel cancer immunotherapies. With over €534 million under management, Jeito's integrated team of experts spans the entire drug development value chain, offering portfolio companies not only capital but also strategic guidance in areas like regulatory affairs, clinical trials, and commercialization. Jeito’s investment approach is also distinguished by its emphasis on global impact, working across Europe and the United States to bring life-saving treatments to market. Jeito has rapidly become a significant player in the life sciences sector, driven by its patient-centered philosophy and focus on fostering the growth of biotech companies that are on the cutting edge of medical innovation.